BBH Stock UPDATES Biotech ETF Market Vectors (BBH) 113.38 10/29/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biotech ETF Market Vectors (BBH) 113.38 $BBH

The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, Market Vectors Biotech ETF and PowerShares Dynamic Biotechnology & Genome Portfolio- GENOME
PR Newswire - Fri Oct 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), SPDR S&P Biotech ETF (AMEX:XBI-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and PowerShares Dynamic Biotechnology & Genome Portfolio - GENOME (AMEX BE-Free Report).
FBT: 97.68 (-0.61), XBI: 169.62 (-1.89), BBH: 113.38 (-1.17)

The Complete Guide to Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 11:09AM CDT
Biotech sector appears to be back on track with fundamentals remaining attractive.
PBE: 49.36 (-0.23), FBT: 97.68 (-0.61), XBI: 169.62 (-1.89), BBH: 113.38 (-1.17), IBB: 290.63 (-3.32)

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
PBE: 49.36 (-0.23), GILD: 110.72 (-2.73), BBH: 113.38 (-1.17), IBB: 290.63 (-3.32)

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
BIIB: 315.06 (-2.97), PBE: 49.36 (-0.23), GILD: 110.72 (-2.73), FBT: 97.68 (-0.61), XBI: 169.62 (-1.89), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17)

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
BIIB: 315.06 (-2.97), PBE: 49.36 (-0.23), GILD: 110.72 (-2.73), FBT: 97.68 (-0.61), XBI: 169.62 (-1.89), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17)

Last Week's ETF Highlights: MLP and Biotech Funds Soar, Volatility Sinks - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 20, 7:00AM CDT
Which ETFs led the market higher and lower last week?
ZROZ: 109.01 (+0.55), KMI: 38.33 (-0.84), VXX: 31.02 (+0.52), FCG: 15.15 (+0.15), BBH: 113.38 (-1.17), MLPI: 43.87 (unch), CVOL: 1.21 (+0.01)

Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
GILD: 110.72 (-2.73), PJP: 67.01 (-0.06), AMGN: 158.88 (+1.69), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17), CELG: 105.14 (-0.56)

The Fed's Valuation Concerns Put These Growth ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 17, 9:00AM CDT
Thanks to Yellen and her comments, these high growth ETFs could be in focus.
SOCL: 18.55 (-0.43), VB: 113.43 (-0.22), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17), IWM: 113.90 (-0.27)

The Zacks Analyst Blog Highlights:Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech ETF
PR Newswire - Thu Jun 26, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX BE-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
PBE: 49.36 (-0.23), FBT: 97.68 (-0.61), BBH: 113.38 (-1.17)

Vertex Pharma Pushes Biotech ETFs Higher - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 25, 1:00PM CDT
The positive trial results of a cystic fibrosis send Vertex Pharmaceuticals and these biotech ETFs higher on Tuesday trading session.
PBE: 49.36 (-0.23), FBT: 97.68 (-0.61), XBI: 169.62 (-1.89), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17)

Biotech HOLDRs Trust Shares Down 10.5% Since SmarTrend's Sell Call (BBH)
Comtex SmarTrend(R) - Mon Mar 31, 9:27AM CDT
SmarTrend identified a Downtrend for Biotech HOLDRs Trust (AMEX:BBH) on March 7th, 2014 at $100.08. In approximately 3 weeks, Biotech HOLDRs Trust has returned 10.52% as of today's recent price of $89.55.
BBH: 113.38 (-1.17)

3 ETFs Tumble Most on Biotech Sell-off - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Mon Mar 24, 1:00PM CDT
The terrible trading in the biotech stock world sent these ETFs into deep red in Friday session.
BIIB: 315.06 (-2.97), GILD: 110.72 (-2.73), XBI: 169.62 (-1.89), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Nasdaq Glitch Hits ETF Market Too - ETF News And Commentary
Eric Dutram - ZACKS - Fri Aug 23, 10:00AM CDT
More than 100 ETFs trade on the Nasdaq, including several popular funds, leaving many investors in the dark during Thursday's session.
QQQ: 99.81 (-0.37), IAI: 39.55 (+0.10), SQQQ: 34.02 (+0.36), IBB: 290.63 (-3.32), BBH: 113.38 (-1.17), TQQQ: 88.00 (-1.07), NDAQ: 42.43 (+0.61)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

BioAge Labs Faces Lawsuit After Discontinued Trial Shocks Investors

Updated Category News Views 163

BioAge Labs Under Legal Scrutiny Following Trial Halt BioAge Labs, a biopharmaceutical company focused on addressing metabolic diseases, is navigating through a tumultuous phase after announcing the discontinuation of its STRIDES Phase 2 clinical trial for azelaprag. This trial suspension came just a short time after the company went public, raising significant concerns...

Continue Reading
Innovative Safety Device Reduces Distracted Driving Risks

Updated Category News Views 110

Introducing the FALC-EYE: A Lifesaving Invention Distracted driving has become a profound concern on our roads, endangering not only those behind the wheel but everyone sharing the roadway. In response to this critical issue, a dedicated inventor from Minneapolis has developed an innovative safety device called the FALC-EYE. With the goal of keeping drivers focused on the...

Continue Reading
BTC, ETH, DOGE Rally as Trump Supports Crypto Adoption

Updated Category News Views 151

Market Overview In an uplifting turn for the cryptocurrency market, Bitcoin, Ethereum, and Dogecoin experienced notable gains as positive remarks on Bitcoin adoption came from high-profile figures. A significant boost in market sentiment was reflected in recent trading activities, prompting renewed interest among investors. President Trump's Impact on Bitcoin Bitcoin rose...

Continue Reading
Stellantis Faces Challenges as Analysts Adjust Expectations

Updated Category News Views 152

Stellantis Stock Outlook Dims Amid Adjustments Stellantis NV (NYSE: STLA) is experiencing considerable pressure in the stock market as recent updates from analysts suggest a sobering outlook. BofA Securities has made significant revisions to its expectations, slashing the price target from €21 to €16, although the firm maintains a 'Buy' rating on the automotive giant....

Continue Reading
Empowering Homeownership: Freedom Bank's Commitment to Accessibility

Updated Category News Views 91

Freedom Bank's Initiative for Affordable Homeownership Freedom Bank's Mortgage Division has made significant strides in promoting homeownership accessibility, demonstrating their dedication to helping families achieve the dream of owning a home. Their Mortgage Division has disbursed an impressive $405,000 in grant funding aimed at providing necessary assistance for down...

Continue Reading